FDA's discussion paper on generative AI medical devices draws more than 500 comments
RAPS reports stakeholders split on how to regulate genAI-enabled devices, with AdvaMed urging the agency to stay with existing risk-based premarket and postmarket frameworks.
Why it matters
The FDA published the discussion paper in August 2026, proposing a two-axis risk framework for genAI-enabled medical devices and asking when patient-facing functions pose risk, how to assess conversational drift and care escalation, and when postmarket monitoring could take priority over premarket evidence. The comments will shape whether the agency writes new rules for chatbots in medicine or adapts existing device pathways. Watch for FDA draft guidance that responds to the docket.
Key facts
- More than 500 comments submitted
- Discussion paper published in August 2026
- Proposes a two-axis risk framework
- AdvaMed backs existing risk-based frameworks